Professor Shi Jiahai is an Assistant Professor (PhD supervisor) at the National University of Singapore School of Medicine, a Bachelor of Xiamen University, PhD of the National University of Singapore, and a Massachusetts Institute of Technology postdoctoral fellow.

He has twenty years of experience in the development of original, innovative drugs, and participated in the development of the hepatitis E virus vaccine. During the doctoral period, he proved that the dimer interface of the main protease of SARS coronavirus is a potential virus drug target. During the postdoctoral period, he studied under Harvey Lodish and participated in creating the first generation of an engineered red blood cell therapy platform.

Professor Shi is now participating in creating engineered extracellular vesicle gene therapy and with this technology, he has become the co-scientific founder and scientific advisor of Carmine Therapeutic. He further developed the second-generation engineered red blood cell therapy platform and he has become the scientific founder and scientific advisor of Carcell Biopharma. Professor Shi also developed the world's first platform technology for preparing shark nano-antibodies by immunising sharks that can be bred, and he established Jotbody to focus on camel and shark nano-antibody discovery services and life science tools.

(Updated as Feb 2024)